Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Point-of-Care Testing » Spartan Bioscience Targeting Alzheimer's Drug Trials With New Near-Patient APOE Test

Spartan Bioscience Targeting Alzheimer's Drug Trials With New Near-Patient APOE Test

Jul 27, 2016
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – After launching the "world's smallest" PCR-based diagnostic device less than two months ago, Spartan Bioscience this week announced the first official test on the system — a 30-minute cheek swab assay for mutations in the apolipoprotein E (APOE) gene.

The target market for the research-use only test is pharmaceutical companies, to help focus and speed up Alzheimer's disease-related clinical trials, Spartan's CEO Paul Lem said in an interview.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

German Shepherd's Own Sequence

A German shepherd called Nala has had her genome sequenced.

And Now Serology Tests

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Young at Brain

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

What's Popular?

In Neurological & Psychological Disorders

  1. Depression GWAS Based on Minimal Phenotyping May Lead to Skewed Results

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.